Lyra therapeutics announces closing of $100.5 million private placement

Private placement priced at-the-market under nasdaq rules proceeds to support lyra's ongoing clinical development of lyr-210 and lyr-220 proceeds, combined with existing cash and expected milestone payments, supports extension of cash runway into mid-2024 watertown, mass. , april 13, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ent) passages, today announced the closing of its previously announced private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million.
LYRA Ratings Summary
LYRA Quant Ranking